JP2008526706A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008526706A5 JP2008526706A5 JP2007548771A JP2007548771A JP2008526706A5 JP 2008526706 A5 JP2008526706 A5 JP 2008526706A5 JP 2007548771 A JP2007548771 A JP 2007548771A JP 2007548771 A JP2007548771 A JP 2007548771A JP 2008526706 A5 JP2008526706 A5 JP 2008526706A5
- Authority
- JP
- Japan
- Prior art keywords
- prevention
- treatment
- disorder
- general formula
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000002265 prevention Effects 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 3
- 206010001897 Alzheimer's disease Diseases 0.000 claims 2
- 206010003736 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
- 206010057668 Cognitive disease Diseases 0.000 claims 2
- 206010010904 Convulsion Diseases 0.000 claims 2
- 206010012601 Diabetes mellitus Diseases 0.000 claims 2
- 206010013754 Drug withdrawal syndrome Diseases 0.000 claims 2
- 208000002551 Irritable Bowel Syndrome Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 206010061920 Psychotic disease Diseases 0.000 claims 2
- 230000001149 cognitive Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drugs Drugs 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1H-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims 1
- 206010002855 Anxiety Diseases 0.000 claims 1
- 206010057666 Anxiety disease Diseases 0.000 claims 1
- 206010004938 Bipolar disease Diseases 0.000 claims 1
- 206010006550 Bulimia nervosa Diseases 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- 208000008208 Craniocerebral Trauma Diseases 0.000 claims 1
- 206010061428 Decreased appetite Diseases 0.000 claims 1
- 206010012335 Dependence Diseases 0.000 claims 1
- 206010013663 Drug dependence Diseases 0.000 claims 1
- 206010015037 Epilepsy Diseases 0.000 claims 1
- 201000001971 Huntington's disease Diseases 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 208000001652 Memory Disorders Diseases 0.000 claims 1
- 206010027599 Migraine Diseases 0.000 claims 1
- 208000008085 Migraine Disorders Diseases 0.000 claims 1
- 208000009025 Nervous System Disease Diseases 0.000 claims 1
- 206010053643 Neurodegenerative disease Diseases 0.000 claims 1
- SNICXCGAKADSCV-JTQLQIEISA-N Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 1
- 229960002715 Nicotine Drugs 0.000 claims 1
- 229940005483 OPIOID ANALGESICS Drugs 0.000 claims 1
- 206010033664 Panic attack Diseases 0.000 claims 1
- 206010061536 Parkinson's disease Diseases 0.000 claims 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 claims 1
- 206010039911 Seizure Diseases 0.000 claims 1
- 206010039966 Senile dementia Diseases 0.000 claims 1
- 206010040984 Sleep disease Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 230000036528 appetite Effects 0.000 claims 1
- 235000019789 appetite Nutrition 0.000 claims 1
- 201000006287 attention deficit hyperactivity disease Diseases 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 230000001684 chronic Effects 0.000 claims 1
- 229960003920 cocaine Drugs 0.000 claims 1
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims 1
- ZPUCINDJVBIVPJ-BARDWOONSA-N cocaine Natural products O([C@@H]1C[C@H]2CC[C@H](N2C)[C@@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-BARDWOONSA-N 0.000 claims 1
- 230000019771 cognition Effects 0.000 claims 1
- 230000037410 cognitive enhancement Effects 0.000 claims 1
- 230000036461 convulsion Effects 0.000 claims 1
- 230000001419 dependent Effects 0.000 claims 1
- 230000002708 enhancing Effects 0.000 claims 1
- 230000037406 food intake Effects 0.000 claims 1
- 235000012631 food intake Nutrition 0.000 claims 1
- 230000001146 hypoxic Effects 0.000 claims 1
- 201000008895 mood disease Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 229930015196 nicotine Natural products 0.000 claims 1
- 201000008430 obsessive-compulsive disease Diseases 0.000 claims 1
- 230000003364 opioid Effects 0.000 claims 1
- 230000001105 regulatory Effects 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
Claims (4)
- 請求項１７〜３１のいずれかに記載の一般式Ｉａの少なくとも１つの化合物を含む、食物摂取に関連する障害又は疾患の予防及び／又は治療のため、食欲の調節のため、体重の維持、増加又は減少のため若しくは肥満、過食症、拒食症、悪液質又はＩＩ型糖尿病（インスリン非依存性糖尿病）の予防及び／又は治療のため、肥満の予防及び／又は治療のための医薬組成物。
- 請求項１７〜３１のいずれかに記載の一般式Ｉａの少なくとも１つの化合物を含む、発作；片頭痛；頭部外傷；てんかん；過敏性大腸症候群；過敏性腸症候群；中枢神経系の障害；不安；パニック発作；うつ病；双極性障害；強迫性障害；認知障害；精神病に関連する認知機能障害；記憶障害；老年認知症；気分障害；睡眠障害；精神病；アルツハイマー病、パーキンソン病、ハンチントン病及び多発性硬化症からなる群より選択される、神経変性障害；統合失調症；慢性間欠性低酸素症；痙攣；又は多動性障害（ＡＤＨＤ、注意欠陥／多動性障害）の予防及び／又は治療のための医薬組成物。
- 請求項１７〜３１のいずれかに記載の一般式Ｉａの少なくとも１つの化合物を含む、使用認知の改善（認知増強）のため及び／又は認知記憶の改善（認知記憶増強）のための医薬組成物。
- 請求項１７〜３１のいずれかに記載の一般式Ｉａの少なくとも１つの化合物を含む、薬物嗜癖及び／又は薬物離脱症状の予防及び／又は治療のため、ベンゾジアゼピン、コカインのような天然、半合成又は合成オピオイド、エタノール及び／又はニコチンからなる群より選択される１以上の薬剤に関連する嗜癖及び／又は離脱症状の予防及び／又は治療のための医薬組成物。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04380288A EP1676842A1 (en) | 2004-12-30 | 2004-12-30 | Nitro-substituted phenyl-piperazine compounds, their preparation and use in medicaments |
| PCT/EP2005/014191 WO2006069808A2 (en) | 2004-12-30 | 2005-12-29 | Nitro-substituted phenyl-piperazine compounds, their preparation and use in medicaments |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008526706A JP2008526706A (ja) | 2008-07-24 |
| JP2008526706A5 true JP2008526706A5 (ja) | 2009-02-19 |
Family
ID=34931899
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007548771A Pending JP2008526706A (ja) | 2004-12-30 | 2005-12-29 | ニトロ置換フェニル−ピペラジン化合物、それらの調製及び薬剤におけるそれらの使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20080176854A1 (ja) |
| EP (2) | EP1676842A1 (ja) |
| JP (1) | JP2008526706A (ja) |
| CN (1) | CN101133042A (ja) |
| AT (1) | ATE529415T1 (ja) |
| CA (1) | CA2592852A1 (ja) |
| ES (1) | ES2375817T3 (ja) |
| MX (1) | MX2007007688A (ja) |
| WO (1) | WO2006069808A2 (ja) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003220222A1 (en) | 2002-03-13 | 2003-09-29 | Signum Biosciences, Inc. | Modulation of protein methylation and phosphoprotein phosphate |
| KR20070097590A (ko) | 2005-01-25 | 2007-10-04 | 에픽스 델라웨어, 인코포레이티드 | 치환된 아릴아민 화합물 및 5―ｈｔ6 조절제로서의 이의용도 |
| US7923041B2 (en) | 2005-02-03 | 2011-04-12 | Signum Biosciences, Inc. | Compositions and methods for enhancing cognitive function |
| WO2006084033A1 (en) | 2005-02-03 | 2006-08-10 | Signum Biosciences, Inc. | Compositions and methods for enhancing cognitive function |
| ES2358288T3 (es) | 2007-08-01 | 2011-05-09 | Laboratorios Del Dr. Esteve S.A. | Combinación de al menos dos ligandos de 5ht6. |
| EP2282735B1 (en) | 2008-04-21 | 2019-01-16 | Signum Biosciences, Inc. | Pp2a modulators for treating alzheimer, parkinson, diabetes |
| GB201002563D0 (en) * | 2010-02-15 | 2010-03-31 | Cambridge Entpr Ltd | Compounds |
| FR2976942B1 (fr) * | 2011-06-23 | 2013-07-12 | Metabolys | Derives de piperazine, leurs procedes de preparation et leurs utilisations dans le traitement de l'insulinoresistance |
| JP5949070B2 (ja) * | 2012-04-03 | 2016-07-06 | Jsr株式会社 | 液晶配向剤、液晶配向膜及び液晶表示素子 |
| CN104884452A (zh) | 2012-11-20 | 2015-09-02 | 沃泰克斯药物股份有限公司 | 用作吲哚胺2,3-二氧化酶的抑制剂的化合物 |
| EP3548034A4 (en) * | 2016-12-05 | 2020-07-08 | Microbiotix, Inc. | BROADBAND SPECTRUM INHIBITORS OF FILOVIRUS |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2712591B1 (fr) * | 1993-11-19 | 1996-02-09 | Pf Medicament | Nouvelles arylpipérazines dérivées d'indole, leur préparation et leur utilisation thérapeutique. |
| CN1329382C (zh) * | 2001-05-11 | 2007-08-01 | 比奥维特罗姆股份公司 | 治疗肥胖、ⅱ型糖尿病和cns－疾病的芳基磺酰胺化合物 |
| CA2445653A1 (en) * | 2001-06-11 | 2002-12-19 | Biovitrum Ab | Substituted sulfonamide compounds, process for their use as medicament for the treatment of cns disorders, obesity and type ii diabetes |
| GB0305575D0 (en) * | 2003-03-11 | 2003-04-16 | Glaxo Group Ltd | Novel compounds |
| JP5335191B2 (ja) * | 2003-08-22 | 2013-11-06 | デンドレオン コーポレイション | Ｔｒｐ−ｐ８発現に関連する疾患の処置をするための組成物および方法 |
| CN101084208A (zh) * | 2004-10-22 | 2007-12-05 | 詹森药业有限公司 | 作为c－fms激酶抑制剂的芳族酰胺 |
| KR20070097590A (ko) * | 2005-01-25 | 2007-10-04 | 에픽스 델라웨어, 인코포레이티드 | 치환된 아릴아민 화합물 및 5―ｈｔ6 조절제로서의 이의용도 |
-
2004
- 2004-12-30 EP EP04380288A patent/EP1676842A1/en not_active Withdrawn
-
2005
- 2005-12-29 MX MX2007007688A patent/MX2007007688A/es not_active Application Discontinuation
- 2005-12-29 WO PCT/EP2005/014191 patent/WO2006069808A2/en active Application Filing
- 2005-12-29 CN CNA2005800488245A patent/CN101133042A/zh active Pending
- 2005-12-29 ES ES05824122T patent/ES2375817T3/es active Active
- 2005-12-29 AT AT05824122T patent/ATE529415T1/de not_active IP Right Cessation
- 2005-12-29 US US11/813,247 patent/US20080176854A1/en not_active Abandoned
- 2005-12-29 JP JP2007548771A patent/JP2008526706A/ja active Pending
- 2005-12-29 CA CA002592852A patent/CA2592852A1/en not_active Abandoned
- 2005-12-29 EP EP05824122A patent/EP1851210B1/en not_active Not-in-force
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008526706A5 (ja) | ||
| JP2008524262A5 (ja) | ||
| JP2009538867A5 (ja) | ||
| ATE203023T1 (de) | Tropanderivate, deren herstellung und verwendung | |
| JP2008044931A5 (ja) | ||
| HRP20090640T1 (hr) | Kristalinični oblici (r)-8-kloro-1-metil-2,3,4,5-tetrahidro-1h-3-benzazepin hidroklorida | |
| EA200970310A1 (ru) | Сульфонилпиразольные и сульфонилпиразолиновые производные карбоксамидина как антагонисты 5-ht | |
| JP2005524713A5 (ja) | ||
| JP2009538869A5 (ja) | ||
| UA105629C2 (uk) | Похідні арилсульфоніл піразолін карбоксамідину як антагоністи 5-нт6 | |
| JP2009538870A5 (ja) | ||
| JP2005521671A5 (ja) | ||
| WO2007076875A3 (en) | Compounds acting on the serotonin transporter | |
| JP2006520766A5 (ja) | ||
| JP2008519056A5 (ja) | ||
| JP2012508275A5 (ja) | ||
| JP2009502914A5 (ja) | ||
| NO20091480L (no) | Aminometyl-2-imidazoler med affinitet mot sporamin-assosierte reseptorer | |
| MX2009005509A (es) | 2-aminoquinolina como los antagonistas de los receptores 5-hidroxitriptamina 5a (5-ht5a). | |
| JP2015521642A5 (ja) | ||
| JP2009537599A5 (ja) | ||
| TW200813006A (en) | New compounds III | |
| JP2005530814A5 (ja) | ||
| WO2003016274A3 (en) | 2-substituted piperidines that are ligands for monoamine receptors and transporters | |
| JP2015521643A5 (ja) |